Condition: Primary Extra-cranial Solid Tumor · Recurrent or Refractory Glypican 3 (GPC3) · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
This description comes directly from the study's public registry record.
Michael Ortiz, MD · 1-833-675-5437 · ortizm2@mskcc.org
Julia Glade Bender, MD · 1-833-675-5437
Always discuss trial participation with your own doctor first.
| Children's Hospital of Los Angeles (Data Collection Only) | Los Angeles, California, United States | Recruiting |
| Children's Healthcare of Atlanta (Data Collection Only) | Atlanta, Georgia, United States | Recruiting |
| Dana Farber Cancer Institute (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04928677